Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q1 2024 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, May 15, 2024

  1. Slide 1: Presentation of Interim Report Q1

    Surgical Science Presentation of Interim Report Q1 May 15, 2024 ©2023 Surgical Science. | All Rights Reserved.

  2. Slide 2: CEO comments – Q1

    Revenues by Region CEO comments – Q1 (MSEK) 160 143 India; 8 141 ▪ Nosedive for Edu Products, -45% revenue 140 12,0 China; 12 120 - Customers starting the year with a tight grip on the wallet 35,8 Backlog; 17 100 - Simulators in Edu Int was the large delta, SEKm -60 compared to Q1, 2023 79 Large ten

  3. Slide 3: Q1: Edu weak, Indu/OEM strong development

    Q1: Edu weak, Indu/OEM strong development SEKm Q1: 250 ▪ Net sales was down 18% to SEKm 200 38% 188.2 (229.1). In local currencies 38% 46% -18%. 33% 41% 40% 150 36% ▪ Educational Products’ sales was down 39% 58% 45%. Excl. orderbook effect Q1 2023 100 -37%. Several coinciding factors - 67% 62% 62% C

  4. Slide 4: Revenue streams – very strong Indu sim rev's

    REVENUE STREAMS – very strong Indu sim rev’s SEKm 250 3% ▪ License rev’s: 34 (31) percent of 2% 5% 2% 6% 3% total revenues. Lumpy for new 25% 200 6% 31% 33% 5% entrants, revenues from several 8% 20% 8% 35% 26% customers. 150 24% 8% 8% 34% 22% 10% 9% 10% 9% ▪ Simulator sales down, Q1 2023. 100 9% 13%

  5. Slide 5: Costs and EBIT margin Q1 2024 – good cost control

    COSTS AND EBIT MARGIN Q1 2024 – good cost control ▪ Gross margin 66% (69). Increased share of license revenues (34 vs 31%) had a positive effect. Product mix unfavorable. Fewer Costs of goods sold 34% (31) simulators means higher fixed costs per Sales costs 21% (20) simulator. Administration costs 8

  6. Slide 6: Organization – 60+ markets covered

    ORGANIZATION No of employees at end of period: 265 (252) Men 191 (183) Women 74 (69) Israel 136 (126) Sweden 58 (58) 60+ markets covered USA 56 (53) Other 15 (15) * Offices / Development sites ©2023 Surgical Science. | All Rights Reserved.

  7. Slide 7: Adjusted EBIT

    ADJUSTED EBIT SEKm 250 50% Q1: 45% ▪ Adjusted EBIT SEKm 200 40% 32.0 (59.3), margin 35% 17% (26). 150 30% 25% 100 20% 15% 50 10% 5% 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2022 2023 2024 Net sales Adjusted EBIT Adjusted EBIT % ©2023 Surgical Science. | All Rights Reserved.

  8. Slide 8: Finance net and taxes

    FINANCE NET AND TAXES ▪ Finance net for the quarter SEKm 1.9 (1.8). Interest on bank balances, revaluation of internal loans towards subsidiaries and IFRS16 effect. ▪ Net result for the quarter SEKm 23.8 (49.8). ©2023 Surgical Science. | All Rights Reserved.

  9. Slide 9: Cash flow

    CASH FLOW SEKm 700 30% ▪ Cash flow from operating activities SEKm 28.5 (60.5). Change in 600 25% working capital SEKm -14.1 (-6.1). 500 Inventory and A/R increased 20% somewhat, other current liabilities 400 15% also increased. 300 ▪ Cash flow from investing activities 200 10% mainly investments in

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com Gisli Hennermark, CEO gisli.hennermark@surgicalscience.com Anna Ahlberg, CFO anna.ahlberg@surgicalscience.com

Surgical Science Sweden — Q1 2024 Earnings Presentation on 6ix